MindMed, working in collaboration with the University Hospital Basel, presented the positive top-line findings on their trial with LSD for anxiety. The data was shared first at the PSYCH Symposium 2022.
The latest article from Shayla Love explores psychedelic patents and how the flaws with the current patent system in the U.S. are leading to some contentious patents.
Wesana Health has announced that following the successful completion of an initial tranche of its previously announced private placement, the company has determined to move forward with a strategic review of Wesana’s care delivery division. Wesana may sell its clinics to focus on drug development.
COMPASS Pathways has announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first-ever mechanistic study of psilocybin in autistic adults.
In this pilot study, the treatment of war veterans with psilocybin was studied, and the emotional well-being of the veterans was monitored. While some research has been done on treatments with psilocybin, no studies were found that specifically targeted war veterans as the study group. Psychedelic Insights breakdown some of the recent preliminary findings from …
Clerkenwell Health is set to open Europe’s first commercial facility for psychedelic drug trials in London, with the goal of making the UK a global leader in psychedelics research and innovation.
Anna Heim of TechCrunch speaks with members of five of the most prominent venture capitalists in the psychedelic space: Palo Santo, Vine Ventures, PsyMed Ventures, Neo Kuma and the Noetic Fund.
COMPASS Pathways has announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from two investigator-initiated studies.
Field Trip Health has announced that it has received unanimous board approval to complete a reorganization that will result in the separation of its Field Trip Discovery and Field Trip Health divisions into two independent public companies. Field Trip Discovery will be renamed Reunion Neuroscience Inc. and Field Trip Health will be renamed Field Trip …
TRYP Therapeutics has announced that the first patient has been dosed in the Company’s Phase II clinical trial for its lead candidate, TRP-8802. In combination with psychotherapy, TRP-8802 is intended to serve as a potential treatment for Binge Eating Disorder.